Genmab stock gains support as Barclays lifts target after warrant-driven share issue

Genmab A/S (ISIN DK0010272202) stock is back in the spotlight after Barclays lifted its price target to DKK 2,900 on September 8, 2026, signaling increased upside from the recent Nasdaq Copenhagen close of DKK 2,141.00 as of September 7, 2026.

Barclays raises target and highlights upside

On September 8, 2026, Barclays analyst Charles Pitman maintained a Buy rating on Genmab stock and set a new price target of DKK 2,900.00, up from a previous target of DKK 2,500.00, according to The Globe and Mail. This 400 DKK increase represents a 16.0 percent uplift in the broker’s own target and places Barclays clearly above the average analyst objective of around DKK 2,625.00 for Genmab.

As of the latest overview reported on September 8, 2026, Barclays new DKK 2,900 target stands meaningfully above a consensus that MarketScreener cites at DKK 2,453.79, implying roughly 18.2 percent more upside than the broader analyst pool estimates, according to Ad-hoc-news. From the September 7, 2026 close at DKK 2,141.00 on Nasdaq Copenhagen, the MarketScreener average target of DKK 2,453.79 implies approximately 14.6 percent upside, while Barclays more optimistic view points to even greater potential.

According to the same MarketScreener-based summary, Genmab shares recorded a one-year high of DKK 2,257.00 and a one-year low of DKK 1,512.00, leaving the September 7, 2026 closing level of DKK 2,141.00 about 5.1 percent below the one-year high and comfortably above the low, as reported by Ad-hoc-news. For investors, that positioning shows the stock trading nearer the upper end of its documented one-year corridor but still short of prior peaks even as analysts collectively point to double-digit percentage upside.

Employee warrant exercises add modest dilution

Alongside the analyst support, Genmab is executing a small capital increase tied to employee incentives. On September 8, 2026, Genmab announced that it will issue 28,011 new shares following the exercise of employee warrants, increasing its share capital by about 0.04 percent and raising approximately DKK 44.3 million in cash proceeds, according to Yahoo Finance. The new shares are subscribed at exercise prices ranging from DKK 1,334.50 to DKK 1,948.00 per share, reflecting the value employees place on Genmab’s long-term prospects.

Following this warrant exercise, Genmab’s total nominal share capital rises to DKK 62,405,855, made up of 62,405,855 shares with a nominal value of DKK 1 each, corresponding to the same number of votes, as detailed in the capital increase announcement on September 8, 2026 by Yahoo Finance. For existing shareholders, the roughly 0.04 percent dilution is incremental, while the warrant proceeds bolster Genmab’s balance sheet and financial flexibility.

A separate report summarizing the warrant exercises noted that market participants largely took the news in stride, with Genmab shares closing the September 8, 2026 session with only a moderate move relative to broader equity indices, underlining that investors see the employee incentive plan as a routine, manageable element of the company’s capital structure, as covered by Bitget.

Scale of Genmab and analyst expectations

Beyond near-term capital moves, Genmab continues to be viewed as a significant player in antibody-based therapeutics. One global market capitalization overview as of early September 2026 estimates Genmab’s equity value at about USD 20.65 billion, based on a share price of USD 33.60 for its American depositary shares, placing the company among mid-sized large-cap healthcare names globally, according to Ad-hoc-news. The combination of a sizable market capitalization and a focused antibody platform helps explain why analysts maintain constructive views even as the stock trades near the upper part of its one-year range.

Consensus estimates compiled in early September 2026 point to continued top-line growth. For the current year 2026, analysts following Genmab project average revenue of about DKK 28.95 billion, rising to DKK 33.71 billion in 2027, with the high end of estimates reaching DKK 29.93 billion for 2026 and DKK 36.74 billion for 2027, according to an overview on Yahoo Finance. Those projections imply double-digit revenue growth in 2027 versus 2026 and underpin the supportive stance taken by major brokers.

On the earnings side, the same analysis shows a current year 2026 consensus for earnings per share of USD 1.13 and a next year 2027 estimate of USD 1.59 for Genmab, representing an anticipated EPS increase of about 40.7 percent year on year based on the compiled forecasts, according to Yahoo Finance. While the overview also highlights that EPS in 2026 is expected to be about 36.2 percent below the prior year level of USD 1.77, the rebound forecast for 2027 suggests analysts are looking through near-term earnings volatility toward renewed growth.

Extraordinary general meeting adds governance angle

Corporate governance and shareholder engagement are also part of the current Genmab story. The company has called an Extraordinary General Meeting to be held on October 7, 2026 at its Copenhagen headquarters, with the announcement made on September 8, 2026, according to TipRanks. The agenda will focus on board remuneration and wider shareholder outreach, giving investors another opportunity to scrutinize governance structures and long-term strategic priorities.

According to the same company announcements page, Genmab has invited shareholders to review detailed materials, including a shareholder letter and video message, ahead of the October 7, 2026 meeting, as reported by TipRanks. For investors, the EGM is an additional checkpoint alongside financial results and analyst commentary, especially as board pay and shareholder communication can influence perceptions of alignment between management and owners.

TipRanks also notes that, based on its AI-driven Spark analyst, Genmab’s American depositary shares carry a Neutral classification even as the most recent individual analyst rating on GMAB is a Buy with a USD 43.00 price target, underscoring that while there is clear directional support from some brokers, broader sentiment remains balanced between upside expectations and an awareness of risks in the biotech and oncology space, as described on TipRanks.

Genmab stock near upper part of one-year range

In Copenhagen trading, the reference price for Genmab stock is the Nasdaq Copenhagen close of DKK 2,141.00 as of September 7, 2026, a level that marked a daily decline of 1.11 percent but a year-to-date gain of 5.62 percent, according to figures summarized from MarketScreener and cited by Ad-hoc-news. With a documented one-year high of DKK 2,257.00 and a one-year low of DKK 1,512.00, that DKK 2,141.00 close leaves the stock trading near the upper end of its range but still with room to revisit the high if catalysts and sentiment remain supportive.

More news and analyses on Genmab stock